CD8A and neoplasm: For instance, tumour ECs are capable of boosting the level of Fas ligand (FasL) and thereby selectively kill effector CD8+ T cells in the presence of tumour-derived VEGF, prostaglandin E2 and IL-10 stimulation [2,129].